Meet Dr. Zeevi, Our CSO, and her Accomplishments!
The MAIN FORCE behind wrapping up the company's USPTO Skin Disorder Patent Grant!
Dr. Zeevi is a FINISHER!
"I have many more ideas on paper. I only wish that the same thing happens with them.
My hope for the company was for it to be acquired, mainly for the product, because an international marketer is the right entity to bring this product to the market in a way that maximizes its success potential."
Patents by Inventor Oron Yacoby-Zeevi
Oron Yacoby-Zeevi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
• OPIPRAMOL PATCH
Publication number: 20180140610
Abstract: Disclosed herein are compositions that are useful in effecting the transdermal delivery of active agents such as opipramol. More particularly, the disclosed transdermal compositions include an active agent; one or more plasticizers; one or more penetration enhancers; a pressure-sensitive adhesive; and may include one or more hydrophilic polymers.
Type: Application
Filed: September 18, 2015
Publication date: May 24, 2018
Applicant: NeuroDerm, Ltd.
Inventors: Oron YACOBY-ZEEVI, Mara NEMAS
• CRYSTAL FORMS OF APOMORPHINE AND USES THEREOF
Publication number: 20170368052
Abstract: The present invention provides solid crystalline forms of apomorphine free base or a hydrate, solvate, or co-crystals thereof. Such crystalline forms may be advantageous over amorphous forms of apomorphine, e.g., amorphous salt forms such as acid addition salts of apomorphine, because of their increased/greater stability and/or improved pharmacological properties, e.g., decreased adverse reactions at the site of administration. The invention further provides liquid formulations obtained by dissolving said crystalline forms of apomorphine in a solvent, as well as a method for treatment of a neurological or movement disorder, e.g., Parkinson's disease, or a condition associated therewith, by administration of said liquid formulations.
Type: Application
Filed: December 23, 2015
Publication date: December 28, 2017
Inventors: Oron Yacoby-Zeevi, Mara Nemas, Jonathan Cummins, Petra Dieterich
• PHARMACEUTICAL COMPOSITIONS COMPRISING LEVODOPA AMIDE AND USES THEREOF
Publication number: 20170296491
Abstract: The present invention discloses various aqueous pharmaceutical compositions comprising a levodopa amide compound, or a salt thereof, which are stable for at least 24 hours at room temperature, and use thereof in treatment of diseases or disorders characterized by neurodegeneration and/or reduced levels of brain dopamine, e.g., Parkinson's disease.
Type: Application
Filed: November 23, 2016
Publication date: October 19, 2017
Inventors: Oron Yacoby-Zeevi, Mara Nemas, Eduardo Zawoznik, Irena Vainshtok, Einat Sela
• Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
Publication number: 20170196828
Abstract: Disclosed herein are for example, liquid aqueous compositions that include for example an ester or salt of levodopa, or an ester or salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome, dystonia, and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of levodopa and/or carbidopa or ester and/or salt thereof.
Type: Application
Filed: August 23, 2016
Publication date: July 13, 2017
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• CONTINUOUS ADMINISTRATION OF L-DOPA, DOPA DECARBOXYLASE INHIBITORS, CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND COMPOSITIONS FOR SAME
Publication number: 20170157077
Abstract: Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.
Type: Application
Filed: July 13, 2016
Publication date: June 8, 2017
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ACTIVE AGENTS
Publication number: 20170157076
Abstract: Disclosed herein are compositions that are useful in effecting the transdermal delivery of therapeutic agents. More particularly, the disclosed transdermal compositions may include a fatty alcohol (for example, octanol), a terpene (for example, limonene), and an active agent comprising an amine moiety.
Type: Application
Filed: July 8, 2016
Publication date: June 8, 2017
Inventors: Oron Yacoby-Zeevi, Mara Nemas, Eduardo Zawoznik
• DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS
Publication number: 20170157079
Abstract: Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.
Type: Application
Filed: February 21, 2017
Publication date: June 8, 2017
Inventor: Oron Yacoby-Zeevi
• Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-O-methyl transferase inhibitors and compositions for same
Patent number: 9421267
Abstract: Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.
Type: Grant
Filed: November 15, 2011
Date of Patent: August 23, 2016
Assignee: NeuroDerm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Compositions for transdermal delivery of active agents
Patent number: 9415108
Abstract: Disclosed herein are compositions that are useful in effecting the transdermal delivery of therapeutic agents. More particularly, the disclosed transdermal compositions may include a fatty alcohol (for example, octanol), a terpene (for example, limonene), and an active agent comprising an amine moiety.
Type: Grant
Filed: November 15, 2011
Date of Patent: August 16, 2016
Assignee: NeuroDerm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas, Eduardo Zawoznik
• Compositions comprising apomorphine and organic acids and uses thereof
Patent number: 9381249
Abstract: The present invention provides stable liquid or semi-solid pharmaceutical compositions of apomorphine, more particularly compositions comprising apomorphine and an organic acid, which are useful in treatment of neurological or movement diseases or disorders, e.g., Parkinson's disease, or conditions associated therewith.
Type: Grant
Filed: November 18, 2015
Date of Patent: July 5, 2016
Assignee: NeuroDerm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same
Publication number: 20160151317
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Application
Filed: July 1, 2015
Publication date: June 2, 2016
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• COMPOSITIONS COMPRISING APOMORPHINE AND ORGANIC ACIDS AND USES THEREOF
Publication number: 20160067339
Abstract: The present invention provides stable liquid or semi-solid pharmaceutical compositions of apomorphine, more particularly compositions comprising apomorphine and an organic acid, which are useful in treatment of neurological or movement diseases or disorders, e.g., Parkinson's disease, or conditions associated therewith.
Type: Application
Filed: November 18, 2015
Publication date: March 10, 2016
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• METHOD FOR TREATMENT OF PARKINSON'S DISEASE
Publication number: 20160022573
Abstract: The present invention provides a method for treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of a composition comprising carbidopa and levopoda, or pharmaceutically acceptable salts thereof, and concomitant oral administration of a catechol-O-methyl transferase (COMT) inhibitor, e.g., entacapone or tolcapone.
Type: Application
Filed: March 13, 2014
Publication date: January 28, 2016
Applicant: NEURODERM, LTD.
Inventor: Oron Yacoby-Zeevi
• DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS
Publication number: 20150352212
Abstract: Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.
Type: Application
Filed: March 12, 2015
Publication date: December 10, 2015
Inventor: Oron Yacoby-Zeevi
• Continuous administration of dopa decarboxylase inhibitors and compositions for same
Patent number: 9101663
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Grant
Filed: December 7, 2010
Date of Patent: August 11, 2015
Assignee: NeuroDerm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• COMPOSITIONS COMPRISING APOMORPHINE AND ORGANIC ACIDS AND USES THEREOF
Publication number: 20150182523
Abstract: The present invention provides stable liquid or semi-solid pharmaceutical compositions of apomorphine, more particularly composition comprising apomorphine and an organic acid, which are useful in treatment of neurological or movement diseases or disorders, e.g., Parkinson's disease, or conditions associated therewith.
Type: Application
Filed: June 5, 2013
Publication date: July 2, 2015
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Continuous administration of dopa decarboxylase inhibitors and compositions for same
Patent number: 9040589
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Grant
Filed: May 13, 2014
Date of Patent: May 26, 2015
Assignee: NeuroDerm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-O-methyl transferase inhibitors and compositions for same
Patent number: 9040578
Abstract: Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.
Type: Grant
Filed: April 2, 2014
Date of Patent: May 26, 2015
Assignee: NeuroDerm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-O-methyl transferase inhibitors and compositions for same
Patent number: 9040577
Abstract: Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.
Type: Grant
Filed: April 2, 2014
Date of Patent: May 26, 2015
Assignee: NeuroDerm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Continuous administration of dopa decarboxylase inhibitors and compositions for same
Patent number: 9040590
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Grant
Filed: May 13, 2014
Date of Patent: May 26, 2015
Assignee: NeuroDerm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Continuous administration of dopa decarboxylase inhibitors and compositions for same
Patent number: 9040590
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Grant
Filed: May 13, 2014
Date of Patent: May 26, 2015
Assignee: NeuroDerm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same
Publication number: 20140249230
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Application
Filed: May 13, 2014
Publication date: September 4, 2014
Applicant: NEURODERM, LTD.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• CONTINUOUS ADMINISTRATION OF L-DOPA, DOPA DECARBOXYLASE INHIBITORS, CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND COMPOSITIONS FOR SAME
Publication number: 20140249228
Abstract: Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.
Type: Application
Filed: April 2, 2014
Publication date: September 4, 2014
Applicant: NEURODERM, LTD.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• CONTINUOUS ADMINISTRATION OF L-DOPA, DOPA DECARBOXYLASE INHIBITORS, CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND COMPOSITIONS FOR SAME
Publication number: 20140249229
Abstract: Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.
Type: Application
Filed: April 2, 2014
Publication date: September 4, 2014
Applicant: NEURODERM, LTD.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same
Publication number: 20140249231
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Application
Filed: May 13, 2014
Publication date: September 4, 2014
Applicant: NEURODERM, LTD.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Continuous Administration of L-Dopa, Dopa Decarboxylase Inhibitors, Catechol-O-Methyl Transferase Inhibitors and Compositions for Same
Publication number: 20140051755
Abstract: Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.
Type: Application
Filed: November 15, 2011
Publication date: February 20, 2014
Applicant: Neuroderm LTD
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Compositions for Transdermal Delivery of Active Agents
Publication number: 20130338143
Abstract: Disclosed herein are compositions that are useful in effecting the transdermal delivery of therapeutic agents. More particularly, the disclosed transdermal compositions may include a fatty alcohol (for example, octanol), a terpene (for example, limonene), and an active agent comprising an amine moiety.
Type: Application
Filed: November 15, 2011
Publication date: December 19, 2013
Applicant: Neuroderm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas, Eduardo Zawozink
• Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
Publication number: 20130253056
Abstract: Disclosed herein are for example, liquid aqueous compositions that include for example an ester or salt of levodopa, or an ester or salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome, dystonia, and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of levodopa and/or carbidopa or ester and/or salt thereof.
Type: Application
Filed: March 12, 2013
Publication date: September 26, 2013
Applicant: Neuroderm, Ltd.
Inventors: Mara Nemas, Oron Yacoby-Zeevi
• Continuous administration of dopa decarboxylase inhibitors and compositions for same
Patent number: 8193243
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Grant
Filed: May 17, 2010
Date of Patent: June 5, 2012
Assignee: Neuroderm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same
Publication number: 20110269833
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Application
Filed: December 7, 2010
Publication date: November 3, 2011
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Continuous administration of dopa decarboxylase inhibitors and compositions for same
Patent number: 7863336
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Grant
Filed: July 14, 2010
Date of Patent: January 4, 2011
Assignee: Neuroderm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same
Publication number: 20100298429
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Application
Filed: July 14, 2010
Publication date: November 25, 2010
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same
Publication number: 20100298428
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Application
Filed: May 17, 2010
Publication date: November 25, 2010
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Heparanase activity neutralizing anti-heparanase monclonal antibody and other anti-heparanase antibodies
Publication number: 20060269552
Abstract: Specific anti-heparanase antibodies which bind specifically to heparanase having sequence homology to human heparanase, which can be used to treat and diagnose conditions associated with heparanase catalytic activity, for purification of heparanase, and for drug development in heparanase associated conditions are disclosed.
Type: Application
Filed: June 3, 2004
Publication date: November 30, 2006
Inventors: Oron Yacoby-Zeevi, Tuvia Peretz, Daphna Miron, Yinon Shlomi, Iris Pecker, Maty Ayal-Hershkovitz
• Methods of and pharmaceutical compositions for improving implantation of embryos
Publication number: 20060008892
Abstract: Methods of improving embryo implantation are disclosed and comprise contacting a receptive uterus and/or an embryo with an effective amount of heparanase and implanting the embryo in the receptive uterus.
Type: Application
Filed: June 17, 2005
Publication date: January 12, 2006
Applicant: Insight Strategy & Marketing Ltd.
Inventor: Oron Yacoby-Zeevi
• Therapeutic and cosmetic uses of heparanases
Publication number: 20050260187
Abstract: Methods and compositions for inducing and/or accelerating wound healing and/or angiogenesis via the catalytic activity of heparanase are disclosed.
Type: Application
Filed: April 15, 2005
Publication date: November 24, 2005
Inventors: Neta Ilan, Israel Vlodavsky, Oron Yacoby-Zeevi, Iris Pecker, Elena Feinstein
• Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies
Publication number: 20040213789
Abstract: Specific anti-heparanase antibodies which bind specifically to heparanase having sequence homology to human heparanase, which can be used to treat and diagnose conditions associated with heparanase catalytic activity, for purification of heparanase, and for drug development in heparanase associated conditions are disclosed.
Type: Application
Filed: August 22, 2003
Publication date: October 28, 2004
Inventors: Oron Yacoby-Zeevi, Tuvia Peretz, Daphna Miron, Yinon Shlomi, Iris Pecker, Maty Ayal-Hershkovitz, Elena Feinstein, Joel M. Van Gelder, Israel Vlodavsky, Yael Friedmann
• Introducing a biological material into a patient
Publication number: 20040175371
Abstract: A biological preparation is provided and includes a biological material and a purified, natural or recombinant, extracellular matrix degrading enzyme being externally adhered thereto.
Type: Application
Filed: March 15, 2004
Publication date: September 9, 2004
Inventor: Oron Yacoby-Zeevi
• Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies
Publication number: 20040170631
Abstract: Specific anti-heparanase antibodies which bind specifically to heparanase having sequence homology to human heparanase, which can be used to treat and diagnose conditions associated with heparanase catalytic activity, for purification of heparanase, and for drug development in heparanase associated conditions are disclosed.
Type: Application
Filed: November 28, 2003
Publication date: September 2, 2004
Inventors: Oron Yacoby-Zeevi, Tuvia Peretz, Daphna Miron, Yinon Shlomi, Iris Pecker, Maty Ayal-Hershkovitz, Elena Feinstein, Joel M. Van Gelder, Israel Vlodavsky, Yael Friedmann
• Therapeutic and cosmetic uses of heparanases
Publication number: 20040146497
Abstract: Methods and compositions for inducing and/or accelerating wound healing and/or angiogenesis via the catalytic activity of heparanase are disclosed.
Type: Application
Filed: February 20, 2004
Publication date: July 29, 2004
Inventors: Neta Ilan, Israel Vlodavsky, Oron Yacoby-Zeevi, Iris Pecker, Elena Feinstein
• Methods and kits utilizing heparanase as a diagnostic marker for haemostatic disorders
Publication number: 20040132123
Abstract: Provided is a method of determining a presence, absence, or severity of a haemostatic disorder in a subject. The method is effected by determining a level of heparanase expression or activity in a biological sample obtained from the subject. Also provided are kits for use with the method.
Type: Application
Filed: October 23, 2003
Publication date: July 8, 2004
Inventor: Oron Yacoby-Zeevi
• Use of ecm degrading enzymes for the improvement of cell transplantation
Publication number: 20040033218
Abstract: Cell preparations which comprise cells carrying an extracellular matrix degrading enzyme and methods of using such cell preparations for improving transplantation efficiency of such cells.
Type: Application
Filed: June 12, 2003
Publication date: February 19, 2004
Inventor: Oron Yacoby-Zeevi
• Therapeutic and cosmetic uses of heparanases
Publication number: 20030161823
Abstract: Methods and compositions for inducing and/or accelerating wound healing and/or angiogenesis via the catalytic activity of heparanase are disclosed.
Type: Application
Filed: January 14, 2003
Publication date: August 28, 2003
Inventors: Neta Ilan, Israel Vlodavsky, Oron Yacoby-Zeevi, Iris Pecker, Elena Feinstein
• Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same
Publication number: 20030068806
Abstract: A method of purifying a recombinant heparanase from overexpressing cells or growth medium which comprises adsorbing said recombinant heparanase on an ion-exchange column under low salt conditions, washing said column with low salt solution thereby eluting other proteins, and eluting the recombinant heparanase from said column by a salt gradient or higher salt concentration.
Type: Application
Filed: May 3, 2002
Publication date: April 10, 2003
Inventors: Maty Ayal-Hershkovitz, Iris Pecker, Oron Yacoby-Zeevi
• Method of inducing bone formation
Publication number: 20030031660
Abstract: A method of inducing bone formation in a subject in need thereof, the method comprises administering to the subject a therapeutically effective amount of heparanase. A pharmaceutical composition for inducing bone formation in a subject in need thereof, the pharmaceutical composition comprises, as an active ingredient, a therapeutically effective amount of heparanase, and a pharmaceutically acceptable carrier.
Type: Application
Filed: June 7, 2002
Publication date: February 13, 2003
Applicant: Insight Strategy & Marketing Ltd.
Inventor: Oron Yacoby-Zeevi
• Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same
Patent number: 6475763
Abstract: Bacterial, yeast and animal cells and methods for overexpressing recombinant heparanase in cellular systems, methods of purifying recombinant heparanase therefrom and modified heparanase species which serve as precursors for generating highly active heparanase by proteolysis.
Type: Grant
Filed: January 19, 2000
Date of Patent: November 5, 2002
Assignee: Insight Strategy & Marketing Ltd.
Inventors: Maty Ayal-Hershkovitz, Haim Moskowitz, Daphna Miron, Ayelet Gilboa, Madlene Mimon, Hanna Ben-Artzi, Oron Yacoby-Zeevi, Iris Pecker, Yoav Peleg, Yinon Shlomi
• Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same
Patent number: 6426209
Abstract: A preparation containing an enzymatically inactive form of heparanase, said enzymatically inactive form of heparanase being cleavable into an enzimatically active form of heparanase.
Type: Grant
Filed: August 10, 2000
Date of Patent: July 30, 2002
Assignee: Insight Strategy Marketing Ltd.
Inventors: Maty Ayal-Hershkovitz, Iris Pecker, Oron Yacoby-Zeevi
• Compositions including glycosaminoglycans degrading enzymes and use of same against surface protected bacteria
Patent number: 6423312
Abstract: A method of rendering a surface protected bacteria more susceptible to an anti-bacterial agent effected by subjecting the bacteria to a glycosaminoglycans degrading enzyme.
Type: Grant
Filed: August 27, 1998
Date of Patent: July 23, 2002
Assignee: Insight Strategy & Marketing Ltd.
Inventor: Oron Yacoby-Zeevi
• Methods of and pharmaceutical compositions for improving implantation of embryos
Publication number: 20020088019
Abstract: Methods of improving embryo implantation are disclosed and comprise contacting a receptive uterus and/or an embryo with an effective amount of heparanase and implanting the embryo in the receptive uterus.
Type: Application
Filed: October 17, 2001
Publication date: July 4, 2002
Inventor: Oron Yacoby-Zeevi
• Therapeutic and cosmetic uses of heparanases
Publication number: 20020068054
Abstract: Methods and compositions for inducing and/or accelerating wound healing and/or angiogenesis via the catalytic activity of heparanase are disclosed.
Type: Application
Filed: December 4, 2000
Publication date: June 6, 2002
Applicant: Insight Strategy & Marketing Ltd. and Hadasit Medical Research Services and Development Ltd.
Inventors: Neta Ilan, Israel Vlodavsky, Oron Yacoby-Zeevi, Iris Pecker
• COMPOSITIONS INCLUDING GLYCOSAMINOGLYCANS DEGRADING ENZYMES AND USE OF SAME AGAINST SURFACE PROTECTED BACTERIA
Publication number: 20020064858
Abstract: A method of rendering a surface protected bacteria more susceptible to an anti-bacterial agent effected by subjecting the bacteria to a glycosaminoglycans degrading enzyme.
Type: Application
Filed: August 27, 1998
Publication date: May 30, 2002
Inventor: ORON YACOBY-ZEEVI
• Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same
Patent number: 6348344
Abstract: Bacterial, yeast and animal cells and methods for overexpressing recombinant heparanase in cellular systems, methods of purifying recombinant heparanase therefrom and modified heparanase species which serve as precursors for generating highly active heparanase by proteolysis.
Type: Grant
Filed: March 2, 1999
Date of Patent: February 19, 2002
Assignee: Insight Strategy & Marketing Ltd.
Inventors: Maty Ayal-Hershkovitz, Haim Moskowitz, Daphna Miron, Ayelet Gilboa, Madelene Mimon, Hanna Ben-Artzi, Oron Yacoby-Zeevi, Iris Pecker, Yoav Peleg, Yinon Schlomi
• INTRODUCING A BIOLOGICAL MATERIAL INTO A PATIENT
Publication number: 20010006630
Abstract: A biological preparation is provided and includes a biological material and a purified, natural or recombinant, extracellular matrix degrading enzyme being externally adhered thereto.
Type: Application
Filed: March 2, 1999
Publication date: July 5, 2001
Inventor: ORON YACOBY-ZEEVI
• Use of glycosaminoglycans degrading enzymes for management of airway associated diseases
Patent number: 6153187
Abstract: A method of managing a patient having an accumulation of mucoid, mucopurulent or purulent material containing glycosaminoglycans, the method comprising the step of administering at least one glycosaminoglycans degrading enzyme to the patient in an amount therapeutically effective to reduce at least one of the following: the visco-elasticity of the material, pathogens infectivity and inflammation. An article of manufacture comprising an inhaler including, as an active ingredient, at least one glycosaminoglycans degrading enzyme for generating aerosols including the enzyme for management a patient having an accumulation of mucoid, mucopurulent or purulent material containing glycosaminoglycans.
Type: Grant
Filed: March 25, 1998
Date of Patent: November 28, 2000
Assignee: Insight Strategy & Marketing Ltd.
Inventor: Oron Yacoby-Zeevi
